EN DE
STOCK COMPARISON

Qingdao Baheal Medical vs McKesson: Fair Value & Quality

Both stocks run through our valuation models. Here is how Qingdao Baheal Medical (301015) and McKesson (MCK) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Qingdao Baheal Medical trades at ¥23.87 versus a fair value of ¥19.87 (-17%), while McKesson trades at $870 versus $819 (-6%).
Qingdao Baheal Medical
301015.SHE · CNY · Health Care
-17%
upside to fair value
overvalued
Price¥23.87
Fair Value¥19.87
Quality61/100
McKesson
MCK · USD · Health Care
-6%
upside to fair value
fairly valued
Price$870
Fair Value$819
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Qingdao Baheal MedicalMcKesson
Valuation
20.9×P/E (TTM)21.0×
1.42×P/S (TTM)0.23×
4.29×P/B
12.3×EV/EBITDA13.9×
PEG1.57×
2.8%Dividend yield0.4%
¥0.57Dividend per share$3.17
Profitability
7%Net margin1%
13%Operating margin2%
22%Return on equity
6%Return on assets5%
Growth
-3%Revenue growth (YoY)6%
0.0%Avg. growth/yr (3Y)13.4%
5.0%Avg. growth/yr (5Y)11.1%
Balance & size
0.51×Debt / equity
$2BMarket cap$94B
mixedGrowth qualityhealthy

Qingdao Baheal Medical leads: 6 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Qingdao Baheal Medicalof which business quality 61 · market factors 49 McKessonof which business quality 65 · market factors 63
ProfitabilityMargins and returns on capital today
56
49
Quality GrowthAre margins and returns improving?
27
65
CashflowEarnings quality: real cash, not paper profit
63
47
Fin. StrengthBalance sheet, leverage, solvency risk
65
72
InvestmentDisciplined investing over empire-building
65
76
Low VolatilityCalm price path (market factor)
71
83
MomentumPrice trend over the last 3–12 months (market factor)
36
51
52W MomentumDistance to the 52-week high (market factor)
48
62
Net IssuanceBuybacks instead of dilution
91
100

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Qingdao Baheal Medical

DCF Models¥24.06
Earnings-Based¥10.73
Multiples¥20.74
Asset-Based¥3.14
Growth DCF¥23.90
Economic Profit¥12.02
Growth Earnings¥18.15

16 of 24 models see the stock below the current price.

McKesson

DCF Models$955
Earnings-Based$444
Dividend Discount$57.26
Multiples$848
Growth DCF$922
Economic Profit$497
Growth Earnings$708

13 of 23 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Qingdao Baheal Medical
Bear ¥14.90Fair Value ¥19.87Bull ¥24.83
¥23.87 = current price (white tick)
McKesson
Bear $605Fair Value $819Bull $1,034
$870 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Qingdao Baheal Medical · Health Care

Quality score61 · above median
Fair value upside-17% · above median

McKesson · Health Care

Quality score66 · Top 25%
Fair value upside-6% · above median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Qingdao Baheal Medical trades at ¥23.87 versus a fair value of ¥19.87 (-17%), while McKesson trades at $870 versus $819 (-6%).

McKesson has the higher quality score (66/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.